AstraZeneca Stock

AstraZeneca EBIT

The EBIT of AstraZeneca (AZN.L) as of Aug 22, 2026 is 14.02 B USD. In the previous year, EBIT was 12.68 B USD — a change of 10.54% (higher).

EBIT

14.02 BUSD

YoY

10.54%

Last updated:

In 2026, AstraZeneca's EBIT was 14.02 B USD, a 10.54% increase from the 12.68 B USD EBIT recorded in the previous year.

The AstraZeneca EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2024
12.68 base
Jan 1, 2025
14.02 base
Jan 1, 2026 (e)
28.18 base
Jan 1, 2027 (e)
30.02 base
Jan 1, 2028 (e)
31.95 base
Jan 1, 2029 (e)
34.45 base
Jan 1, 2030 (e)
36.64 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (B USD)
2031 est -
2030 est 36.64
2029 est 34.45
2028 est 31.95
2027 est 30.02
2026 est 28.18
2025 14.02
2024 12.68
2023 8.92
2022 8.83
2021 4.90
2020 4.40
2019 3.79
2018 2.43
2017 3.84
2016 4.10
2015 5.52
2014 5.17
2013 3.71
2012 8.15
2011 11.31
2010 13.20
2009 11.93
2008 10.09
2007 8.31
2006 8.05
Access this data via the Eulerpool API

AstraZeneca Revenue

AstraZeneca Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
54.07 B USD
12.68 B USD
7.04 B USD
Jan 1, 2025
58.74 B USD
14.02 B USD
10.23 B USD
Jan 1, 2026 (e)
62.68 B USD
28.18 B USD
15.85 B USD
Jan 1, 2027 (e)
66.77 B USD
30.02 B USD
17.78 B USD
Jan 1, 2028 (e)
71.06 B USD
31.95 B USD
19.77 B USD
Jan 1, 2029 (e)
76.60 B USD
34.45 B USD
22.99 B USD
Jan 1, 2030 (e)
81.49 B USD
36.64 B USD
25.74 B USD
Jan 1, 2031 (e)
84.98 B USD
0.00 USD
26.45 B USD

AstraZeneca Margins

AstraZeneca stock margins

The AstraZeneca margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AstraZeneca. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AstraZeneca.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
82.14 %
23.46 %
13.01 %
Jan 1, 2025
81.31 %
23.87 %
17.41 %
Jan 1, 2026 (e)
81.31 %
44.97 %
25.29 %
Jan 1, 2027 (e)
81.31 %
44.97 %
26.62 %
Jan 1, 2028 (e)
81.31 %
44.97 %
27.82 %
Jan 1, 2029 (e)
81.31 %
44.97 %
30.02 %
Jan 1, 2030 (e)
81.31 %
44.97 %
31.59 %
Jan 1, 2031 (e)
81.31 %
0.00 %
31.12 %

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing AstraZeneca's EBIT

AstraZeneca's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of AstraZeneca's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

AstraZeneca's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in AstraZeneca’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about AstraZeneca stock

EBIT of AstraZeneca is 14.02 B USD in 2026.

EBIT of AstraZeneca changed from 12.68 B USD to 14.02 B USD, representing a 10.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's AstraZeneca historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — AstraZeneca

All Key Metrics — AstraZeneca